Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in children with Kawasaki disease
NL-OMON52448Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of canakinumab in Kawasaki disease (KD) and vasculitis (2 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoint: Fever-free response at 48 hours. Started Jun 2013; status: recruiting.
02
Drugs
canakinumab
03
Conditions
Kawasaki disease (KD)vasculitis
Beyond the preview
Go deeper on NL-OMON52448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52448.